Accession Number : AD1025926


Title :   Prediction of Metastasis Using Second Harmonic Generation


Descriptive Note : Technical Report,01 May 2015,30 Apr 2016


Corporate Author : University of Rochester Rochester United States


Personal Author(s) : Brown,Edward


Full Text : https://apps.dtic.mil/dtic/tr/fulltext/u2/1025926.pdf


Report Date : 01 Jul 2016


Pagination or Media Count : 14


Abstract : A breast cancer patient with estrogen receptor positive (ER+) invasive ductal carcinoma (IDC) typically has the tumor removed, possibly with nearby lymph nodes, and hormonal therapy is begun. Then a significant decision is made: should the patient receive adjuvant chemotherapy to attack cells that have escaped the tumor? In IDC ER patients whose cancer has spread to the lymph nodes the choice is clear and virtually all are treated systemically. However, in the majority of IDC ER+ cases the cancer has not yet spread (N0), and the choice is unclear. Current data suggests that about half of patients that are systemically treated would not have metastasized, did not need to suffer the toxic effects of systemic therapy, and were overtreated. Hence there is a pressing need to predict who will, and will not, metastasize, to minimize overtreatment. We hypothesize that SHG F/B is a clinically useful predictor of metastatic outcome. In an existing TMA we will answer the following questions: 1) Does F/B predict metastatic outcome in IDC patients? 2) Does F/B predict metastatic outcome in ER+ IDC patients? 3) Does F/B predict metastatic outcome in ER+ IDC patients treated with hormonal, chemo, and/or radiotherapy?


Descriptors :   metastasis , medical research , breast cancer , microscopy , biomedical research , chemotherapy , therapeutics


Distribution Statement : APPROVED FOR PUBLIC RELEASE